FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2530339110> ?p ?o ?g. }

• W2530339110 abstract "Model-based optimization approaches are valuable in developing new drugs for human metabolic disorders. The core objective in most optimal drug designs is positive therapeutic effects. In this study, we considered the effects of therapeutic, adverse, and target variation simultaneously. A fuzzy optimization method was applied to formulate a multiobjective drug design problem for detecting enzyme targets in the presynaptic dopamine metabolic network to remedy two types of enzymopathies caused by deficiencies of vesicular monoamine transporter 2 (VMAT2) and tyrosine hydroxylase (TH). The fuzzy membership approach transforms a two-stage drug discovery problem into a unified decision-making problem. We developed a nested hybrid differential evolution algorithm to efficiently identify a set of potential drug targets. Furthermore, we also simulated the effects of current clinical drugs for Parkinson's disease (PD) in this model and tried to clarify the possible causes of neurotoxic and neuroprotective effects. The optimal drug design could yield 100% satisfaction grade when both therapeutic effect and the number of targets were considered in the objective. This scenario required regulating one to three and one or two enzyme targets for 50%-95% and 50%-100% VMAT2 and TH deficiencies, respectively. However, their corresponding adverse and target variation effect grades were less satisfactory. For the most severe deficiencies of VMAT2 and TH, a compromise design could be obtained when the effects of therapeutic, adverse, and target variation were simultaneously applied to the optimal drug discovery problem. Such a trade-off design followed the no free lunch theorem for optimization; that is, a more serious dopamine deficiency required more enzyme targets and lower satisfaction grade. In addition, the therapeutic effects of current clinical medications for PD could be enhanced in combination with new enzyme targets. The increase of toxic metabolites after treatment might be the cause of neurotoxic effects of some current PD medications." @default.
• W2530339110 created "2016-10-21" @default.
• W2530339110 creator A5051642293 @default.
• W2530339110 creator A5057602145 @default.
• W2530339110 date "2016-10-13" @default.
• W2530339110 modified "2023-09-25" @default.
• W2530339110 title "Fuzzy Decision Making Approach to Identify Optimum Enzyme Targets and Drug Dosage for Remedying Presynaptic Dopamine Deficiency" @default.
• W2530339110 cites W1500036797 @default.
• W2530339110 cites W1578932543 @default.
• W2530339110 cites W18074867 @default.
• W2530339110 cites W1919367720 @default.
• W2530339110 cites W1967225297 @default.
• W2530339110 cites W2000531252 @default.
• W2530339110 cites W2001973024 @default.
• W2530339110 cites W2003049033 @default.
• W2530339110 cites W2003421484 @default.
• W2530339110 cites W2011854027 @default.
• W2530339110 cites W2012557172 @default.
• W2530339110 cites W2017042232 @default.
• W2530339110 cites W2025013804 @default.
• W2530339110 cites W2025925932 @default.
• W2530339110 cites W2030257414 @default.
• W2530339110 cites W2050077524 @default.
• W2530339110 cites W2050531538 @default.
• W2530339110 cites W2051819852 @default.
• W2530339110 cites W2054954256 @default.
• W2530339110 cites W2057190844 @default.
• W2530339110 cites W2059463965 @default.
• W2530339110 cites W2079490675 @default.
• W2530339110 cites W2081658589 @default.
• W2530339110 cites W2103365780 @default.
• W2530339110 cites W2103776834 @default.
• W2530339110 cites W2106030883 @default.
• W2530339110 cites W2117471184 @default.
• W2530339110 cites W2125426232 @default.
• W2530339110 cites W2128579390 @default.
• W2530339110 cites W2129867593 @default.
• W2530339110 cites W2138535275 @default.
• W2530339110 cites W2143959688 @default.
• W2530339110 cites W2148969844 @default.
• W2530339110 cites W2156125169 @default.
• W2530339110 cites W2162258881 @default.
• W2530339110 cites W2170392605 @default.
• W2530339110 cites W2206140810 @default.
• W2530339110 cites W2301404923 @default.
• W2530339110 cites W2334475967 @default.
• W2530339110 cites W2340907198 @default.
• W2530339110 cites W2606051482 @default.
• W2530339110 cites W2606572887 @default.
• W2530339110 cites W4249812240 @default.
• W2530339110 cites W4255920113 @default.
• W2530339110 doi "https://doi.org/10.1371/journal.pone.0164589" @default.
• W2530339110 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5063375" @default.
• W2530339110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27736960" @default.
• W2530339110 hasPublicationYear "2016" @default.
• W2530339110 type Work @default.
• W2530339110 sameAs 2530339110 @default.
• W2530339110 citedByCount "1" @default.
• W2530339110 countsByYear W25303391102017 @default.
• W2530339110 crossrefType "journal-article" @default.
• W2530339110 hasAuthorship W2530339110A5051642293 @default.
• W2530339110 hasAuthorship W2530339110A5057602145 @default.
• W2530339110 hasBestOaLocation W25303391101 @default.
• W2530339110 hasConcept C126255220 @default.
• W2530339110 hasConcept C137183658 @default.
• W2530339110 hasConcept C154945302 @default.
• W2530339110 hasConcept C169760540 @default.
• W2530339110 hasConcept C2776755682 @default.
• W2530339110 hasConcept C2778406628 @default.
• W2530339110 hasConcept C2780035454 @default.
• W2530339110 hasConcept C33923547 @default.
• W2530339110 hasConcept C41008148 @default.
• W2530339110 hasConcept C513476851 @default.
• W2530339110 hasConcept C58166 @default.
• W2530339110 hasConcept C60644358 @default.
• W2530339110 hasConcept C70721500 @default.
• W2530339110 hasConcept C71924100 @default.
• W2530339110 hasConcept C86803240 @default.
• W2530339110 hasConcept C98274493 @default.
• W2530339110 hasConceptScore W2530339110C126255220 @default.
• W2530339110 hasConceptScore W2530339110C137183658 @default.
• W2530339110 hasConceptScore W2530339110C154945302 @default.
• W2530339110 hasConceptScore W2530339110C169760540 @default.
• W2530339110 hasConceptScore W2530339110C2776755682 @default.
• W2530339110 hasConceptScore W2530339110C2778406628 @default.
• W2530339110 hasConceptScore W2530339110C2780035454 @default.
• W2530339110 hasConceptScore W2530339110C33923547 @default.
• W2530339110 hasConceptScore W2530339110C41008148 @default.
• W2530339110 hasConceptScore W2530339110C513476851 @default.
• W2530339110 hasConceptScore W2530339110C58166 @default.
• W2530339110 hasConceptScore W2530339110C60644358 @default.
• W2530339110 hasConceptScore W2530339110C70721500 @default.
• W2530339110 hasConceptScore W2530339110C71924100 @default.
• W2530339110 hasConceptScore W2530339110C86803240 @default.
• W2530339110 hasConceptScore W2530339110C98274493 @default.
• W2530339110 hasLocation W25303391101 @default.
• W2530339110 hasLocation W25303391102 @default.
• W2530339110 hasLocation W25303391103 @default.
• W2530339110 hasLocation W25303391104 @default.
• W2530339110 hasOpenAccess W2530339110 @default.

• next